Browse > Article
http://dx.doi.org/10.5352/JLS.2019.29.1.105

Effects of an Anti-cancer Drug, Tubastatin A, on the Growth and Development of Immature Oocytes in Mice  

Choi, Yun-Jung (Laboratory Animal Resource Center, DGIST)
Min, Gyesik (Department of Nursing, College of Life Science, Gyeongnam National University of Science & Technology)
Publication Information
Journal of Life Science / v.29, no.1, 2019 , pp. 105-111 More about this Journal
Abstract
In recent years, progress has been made in the search for the development of new anti-cancer agents by employing specific inhibitors of histone deacetylase (HDAC)-6 to block signal transduction pathways in cancer cells. This study examined the effects of tubastatin A (TubA), an HDAC-6 inhibitor, on the growth and development of immature oocytes in murine ovaries using RNA sequencing analysis. The results from a gene set enrichment analysis (GSEA) indicated that the expression of most of the gene sets involved in the cell cycle and control and progression of meiosis decreased in the TubA-treated group as compared with that in germinal vesicle (GV) stage oocytes. In addition, an ingenuity pathway analysis (IPA) suggested that TubA not only caused increased expression of p53 and pRB and decreased expression of CDK4/6 and cyclin D but also caused elevated expression of genes involved in the control of the DNA check point in G2/M stage oocytes. These results suggest that TubA may induce cell cycle arrest and apoptosis through the induction of changes in the expression of genes involved in signal transduction pathways associated with DNA damage and the cell cycle of immature oocytes in the ovary.
Keywords
Histone deacetylase-6; oocyte; ovarian cancer; RNA-sequencing; tubastatin A;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shin, H. J., Baek, K. H., Jeon, A. H., Kim, S. J., Jang, K. L., Sung, Y. C., Kim, C. M. and Lee, C. W. 2003. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22, 3853-3858.   DOI
2 Suraweera, A., O'Byrne, K. J. and Richard, D. J. 2018. Combination therapy with Histone Deacetylase Inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi. Front. Oncol. 29, 92.   DOI
3 Takai, N. and Narahara, H. 2010. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J. Oncol. 2010, 458431.
4 Tsuda, H., Yamamoto, K., Inoue, T., Uchiyama, I. and Umesaki, N. 2000. The role of p16-cyclin D/CDK-pRB pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br. J. Cancer 82, 675-682.   DOI
5 Wang, X., Simpson, E. R. and Brown, K. A. 2015. p53: Protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 75, 5001-5007.   DOI
6 Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., Lio, P., Macdonald, H. R. and Trumpp, A. 2008. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 135, 1118-1129.   DOI
7 Yoon, S. and Eom, G. H. 2016. HDAC and HDAC inhibitor: From cancer to cardiovascular disease. Chonnam. Med. J. 52, 1-11.   DOI
8 Yoon, S., Kim, S. Y. and Nam, D. 2016. Improving gene-set enrichment analysis of RNA-seq data with small replicates. PLoS One 11, e0165919.   DOI
9 Zhou, D., Choi, Y. J. and Kim, J. H. 2017. Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice. Sci. Rep. 7, 8131.   DOI
10 Aguirre-Ghiso, J. A. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7, 834-846.   DOI
11 Bolden, J. E., Shi, W., Jankowski, K., Kan, C. Y., Cluse, L., Martin, B. P., MacKenzie, K. L., Smyth, G. K. and Johnstone, R. W. 2013. HDAC inhibitors induce tumor-cell- selective pro-apoptotic transcriptional responses. Cell Death Dis. 4, e519.   DOI
12 Dong, Z., Yang, Y., Liu, S., Lu, J., Huang, B. and Zhang, Y. 2017. HDAC inhibitor PAC-320 induces G2/M cell cycle arrest and apoptosis in human prostate cancer. Oncotarget 9, 512-523.   DOI
13 Chang, J. C. 2016. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore) 95, S20-S25.   DOI
14 Corney, D. C., Flesken-Nikitin, A., Choi, J. and Nikitin, A. Y. Role of p53 and Rb in ovarian cancer. Adv. Exp. Med. Biol. 622, 99-177.
15 Delcuve, G. P., Khan, D. H. and Davie, J. R. 2012. Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors. Clin. Epigenetics 4, 5.   DOI
16 Haakenson, J. and Zhang, X. 2013. HDAC6 and ovarian cancer. Int. J. Mol. Sci. 14, 9514-9535.   DOI
17 Halsall, J. A. and Turner, B. M. 2016. Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success. Bioessays 38, 1102-1110.   DOI
18 Mottamal, M., Zheng, S., Huang, T. L. and Wang, G. 2015. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20, 3898-3941.   DOI
19 Hervouet, E., Cheray, M., Vallette, F. M. and Cartron, P. F. 2013. DNA methylation and apoptosis resistance in cancer cells. Cells 2, 545-573.   DOI
20 Lernoux, M., Schnekenburger, M., Dicato, M. and Diederich, M. 2018. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacol. Res. 129, 337-356.   DOI
21 Phi, L. T. H., Sari, I. N., Yang, Y. G., Lee, S. H., Jun, N., Kim, K. S., Lee, Y. K. and Kwon, H. Y. 2018. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018, 5416923.